LVM Capital Management Ltd. MI Raises Stock Position in Pfizer Inc. (NYSE:PFE)

LVM Capital Management Ltd. MI increased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 313,284 shares of the biopharmaceutical company's stock after acquiring an additional 25,235 shares during the period. LVM Capital Management Ltd. MI's holdings in Pfizer were worth $7,939,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mcdonald Partners LLC increased its position in shares of Pfizer by 9.9% in the fourth quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after purchasing an additional 9,963 shares during the last quarter. Bank of Jackson Hole Trust bought a new position in shares of Pfizer in the 4th quarter worth $264,000. Harvey Capital Management Inc. bought a new position in shares of Pfizer in the 4th quarter worth $544,000. ING Groep NV increased its stake in Pfizer by 48.6% in the fourth quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock valued at $26,881,000 after acquiring an additional 331,403 shares during the last quarter. Finally, WCM Investment Management LLC increased its stake in Pfizer by 128.7% in the fourth quarter. WCM Investment Management LLC now owns 115,913 shares of the biopharmaceutical company's stock valued at $3,062,000 after acquiring an additional 65,238 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.0%

Pfizer stock traded up $0.01 during trading hours on Friday, reaching $23.46. The stock had a trading volume of 56,576,195 shares, compared to its average volume of 41,090,161. The stock has a market cap of $133.38 billion, a PE ratio of 16.64, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a fifty day simple moving average of $23.12 and a 200-day simple moving average of $25.07.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter last year, the firm earned $0.82 EPS. The company's revenue was down 7.8% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Stockholders of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.33%. Pfizer's dividend payout ratio is currently 124.64%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Finally, UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.